Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ERAS-801

Small molecule · Inhibitor of epidermal growth factor receptor (EGFR)

Phase 1 Most advanced trial
1 Registered trials

What is ERAS-801?

ERAS-801 is an orally bioavailable, CNS-penetrating inhibitor that binds and inhibits EGFR, including EGFR amplifications driven by oncogenic variants and wildtype EGFR. It is designed to block EGFR-mediated signaling and is studied in glioblastoma multiforme, including EGFR-driven CNS tumors and CNS metastases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
epidermal growth factor receptor (EGFR)
Mechanism
Inhibitor of epidermal growth factor receptor (EGFR)
Pathways
EGFR signaling, tumor cell proliferation, tumor vascularization
Therapy area
Oncology
In trials of
ERAS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
B68F5P9PB7

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05222802 Phase 1 Glioblastoma Multiforme Active not recruiting ERAS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma Multiforme

Other drugs acting on EGFR

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.